Here are the DEF 14A proxy statements from Abeona Therapeutics Inc. (ABEO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ABEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABEO filings page.
Abeona Therapeutics Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 12, 2026. Investors will elect three Class 1 directors for three-year terms, hold an advisory vote on executive pay, and ratify Deloitte & Touche LLP as auditor for 2026.
Stockholders are also asked to approve increasing shares reserved under the 2023 Equity Incentive Plan from 8,400,000 to 11,500,000 and to amend the Amended and Restated Certificate of Incorporation to remove the advance notice provision for director nominations. Each share of common stock outstanding as of April 15, 2026 has one vote.